Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964493 · ClinicalTrials.gov registry record · Phase 2
TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
A Phase 2 study, sponsored by TenNor Therapeutics Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT03964493 is a Phase 2 study that has completed, run by TenNor Therapeutics Limited. The registered enrollment target is 120 participants.
The verdict
NCT03964493, a Phase 2 study, has completed, sponsored by TenNor Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
Interventions
- DRUG Vancomycin
- DRUG TNP-2092
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-04-20 |
| Est. Completion | 2020-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03964493
The ClinicalTrials.gov registry entry for NCT03964493 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TenNor Therapeutics Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT03964493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03964493 about?
NCT03964493 is a clinical study titled "TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection". The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
What is the current status of trial NCT03964493?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-04-20. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03964493?
The interventions under investigation include: Vancomycin (DRUG), TNP-2092 (DRUG).
Who is sponsoring clinical trial NCT03964493?
This trial is sponsored by TenNor Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.